自体移植失败后DLBCL:异基因移植与CAR-T的非比较队列分析
该非比较注册分析纳入584例自体移植失败后接受减低强度异基因移植或阿基仑赛CAR-T治疗的DLBCL患者,显示两种疗法均可使部分患者获得持久缓解,且CIBMTR预后评分可识别两种治疗后高失败风险患者。
要点
- 自体移植失败后DLBCL,CAR-T与异基因移植均可提供持久缓解。
- CIBMTR预后评分可区分两种治疗后高治疗失败风险患者。
- 高危患者需探索新的复发预防策略。
核心结论
- CAR-T和异基因移植均可使部分自体移植失败后DLBCL患者获得持久缓解。
- 简单CIBMTR预后评分可用于识别两种治疗后高治疗失败风险患者。
研究设计与样本
- 非比较性注册分析,纳入2012至2019年584例≥18岁自体移植失败后DLBCL患者。
- 患者接受减低强度异基因移植或阿基仑赛CAR-T治疗,并将CIBMTR预后模型应用于CAR-T受者。
主要发现
- CAR-T组1年复发率39.5%、非复发死亡率4.8%、总生存率73.4%、无进展生存率55.7%。
- 异基因移植组1年复发率26.2%、非复发死亡率20.0%、总生存率65.6%、无进展生存率53.8%。
- 异基因移植组低、中、高/极高危患者1年总生存率分别为73.3%、59.9%、46.3%(P = .002)。
- CAR-T组低、中、高/极高危患者1年总生存率分别为88.4%、76.4%、52.8%(P < .001)。
临床怎么用
- 对自体移植失败后DLBCL患者,可依据CIBMTR预后评分分层选择CAR-T或异基因移植并识别高危者。
- 高危患者治疗后应考虑加强复发监测及探索新预防策略。
局限性
- 为非比较性注册分析,未直接比较两种疗法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic transplant (alloHCT) and chimeric antigen receptor modified (CAR)-T cell therapy are potentially cuarative options of diffuse large B-cell lymphoma (DLBCL) relapsing after an autologous (auto)HCT. Although the Center for International Blood and Marrow Transplant Research (CIBMTR) prognostic model can predict outcomes of alloHCT in DLBCL after autoHCT failure, corresponding models of CAR-T treatment in similar patient populations are not available. In this noncomparative registry analysis, we report outcomes of patients with DLBCL (≥18 years) undergoing a reduced intensity alloHCT or CAR-T therapy with axicabtagene ciloleucel during 2012 to 2019 after a prior auto-HCT failure and apply the CIBMTR prognostic model to CAR-T recipients. A total of 584 patients were included. The 1-year relapse, nonrelapse mortality, overall survival (OS), and progression-free survival for CAR-T treatment after autoHCT failure were 39.5%, 4.8%, 73.4%, and 55.7%, respectively. The corresponding rates in the alloHCT cohort were 26.2%, 20.0%, 65.6%, and 53.8%, respectively. The 1-year OS of alloHCT recipients classified as low-, intermediate- and high/very high-risk groups according to the CIBMTR prognostic score was 73.3%, 59.9%, and 46.3%, respectively (P = .002). The corresponding rates for low-, intermediate-, and high/very high-risk CAR-T patients were 88.4%, 76.4%, and 52.8%, respectively (P < .001). This registry analysis shows that both CAR-T and alloHCT can provide durable remissions in a subset of patients with DLBCL relapsing after a prior autoHCT. The simple CIBMTR prognostic score can be used to identify patients at high risk of treatment failure after either procedure. Evaluation of novel relapse mitigations strategies after cellular immunotherapies are warranted in these high-risk patients.
引用
- Hamadani M, Gopal AK, Pasquini M, et al. Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. Blood Adv. 2022. PMID: 34673903. doi:10.1182/bloodadvances.2021005788
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。